| General Information of Drug Metabolite (DM) (ID: DM002035) |
| DM Name |
6-OH-fluvastatin
|
|
|
|
|
|
|
|
| Full List of Drug-Metabolizing Enzyme (DME) Related to This DM |
| DME(s) Producing This DM through Metabolism |
| DME Name |
DME ID |
Reactant |
Reaction |
Related Drug |
REF |
|
Cytochrome P450 2C9 (CYP2C9)
|
DME0019
|
| Oxidation - Hydroxylation |
Fluvastatin sodium
|
[1] , [2] , [3] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Full List of Drug(s) That Produce This DM By Metabolism |
| Fluvastatin sodium |
DR0738
|
Approved |
Hypertriglyceridaemia |
|
|
| References |
| 1 |
Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
|
| 2 |
Metabolism and transport of oxazaphosphorines and the clinical implications Drug Metab Rev. 2005;37(4):611-703. doi: 10.1080/03602530500364023.
|
| 3 |
Assessment of ifosfamide pharmacokinetics, toxicity, and relation to CYP3A4 activity as measured by the erythromycin breath test in patients with sarcoma Cancer. 2007 Jun 1;109(11):2315-22. doi: 10.1002/cncr.22669.
|
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.
